title: Molecular-genetic aspects of familial hypercholesterolemia.
abstract: Familial hypercholesterolemia (FH) is the world's most abundant and the most common heritable disorder of lipid metabolism. The prevalence of the disease in general population is 1:500. Therefore the approximate number of FH patients all over the world is 14 million. From the genetic point of view the disease originates as a result of mutations in genes affecting the processing of LDL particles from circulation, resulting in an increase in LDL cholesterol and hence total cholesterol. These are mutations in genes encoding LDL receptor, apolipoprotein B, proprotein convertase subtilisin/kexin 9 and LDL receptor adaptor protein 1. Cholesterol depositing in tissues and blood vessels of individuals creates tendon xanthoma, xanthelesma and arcus lipoides cornae. Due to the increased deposition of cholesterol in blood vessels, atherosclerosis process is accelerated, what leads to a significantly higher risk of premature cardiovascular diseases. Therefore, early clinical diagnosis confirmed by the DNA analysis, and effective treatment are crucial to reduce the mortality and high risk of premature atherosclerotic complications.
authors.forename: D
authors.initials: D
authors.lastname: Gabcova-Balaziova
authors.forename: D
authors.initials: D
authors.lastname: Stanikova
authors.forename: B
authors.initials: B
authors.lastname: Vohnout
authors.forename: M
authors.initials: M
authors.lastname: Huckova
authors.forename: J
authors.initials: J
authors.lastname: Stanik
authors.forename: I
authors.initials: I
authors.lastname: Klimes
authors.forename: K
authors.initials: K
authors.lastname: Raslova
authors.forename: D
authors.initials: D
authors.lastname: Gasperikova
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D053299:Apolipoprotein B-100 / Q000097:blood / Q000235:genetics*; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood; D020022:Genetic Predisposition to Disease; D006801:Humans; D008072:Hyperlipoproteinemia Type I / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D009154:Mutation; D010641:Phenotype; D011237:Predictive Value of Tests; D015995:Prevalence; D011379:Prognosis; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000097:blood / Q000235:genetics*; D011973:Receptors, LDL / Q000097:blood / Q000235:genetics*; D012307:Risk Factors; D012697:Serine Endopeptidases / Q000097:blood / Q000235:genetics*
chemical_list: C569471:APOB protein, human; D000924:Anticholesteremic Agents; D053299:Apolipoprotein B-100; D015415:Biomarkers; C573412:LDLR protein, human; D011973:Receptors, LDL; D002784:Cholesterol; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases